Lurasidone vs Paliperidone palmitate (Invega Sustenna)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Lurasidone
Marketed by Sumitomo Pharma and partners
NCT00549718 · Phase 3 · completed
The study randomized approximately 500 participants to lurasidone 40, 80, or 120 mg or placebo and used quadruple masking of participants, clinicians, investigators, and outcome assessors. Its clinical primary endpoint, change in total PANSS score over 6 weeks, favored lurasidone overall versus placebo and was statistically significant (p<0.05).
Reported efficacy
Mean change in Total PANSS Score From Baseline at Week 6: Change in PANSS total score at week 6 (prespecified primary analysis in the per-protocol set): -26.42±2.02 lurasidone vs -27.33±2.01 quetiapine XR (adjusted mean±SE); difference -0.91 (95% CI -6.35 to 4.53); lower limit above the -8.99 non-inferiority margin, met. The ITT set analysis also showed non-inferiority. (met)
Result source: NCT03465787
Paliperidone palmitate (Invega Sustenna)
Marketed by Johnson & Johnson
NCT00101634 · Phase 3 · completed
The study was randomized and double-blind, with 518 participants and a placebo comparison, and used a clinical symptom measure (change in total PANSS score) as its primary endpoint.
Next expected readout: December 2026 · NCT07493551 (registry estimate)
Reported efficacy
Part-2 (Disease Progression): Time to First Treatment Failure (From Day 1 up to 9 Months); Part 3 (Extended Disease Progression [EDP]): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score (Baseline and 18 Months); Part 3 (Disease Modification): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score (Baseline and Day 260): Treatment failure in Part II (9 months): paliperidone palmitate 29.5% vs oral antipsychotics 24.8%, P=0.377; extended 18-month analysis 28.6% vs 44.4%, P=0.080 (DREaM, Schizophr Res 2022). (missed)
Result source: NCT02431702
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lurasidone | Paliperidone palmitate (Invega Sustenna) |
|---|---|---|
| PANSS total, change | -26.5 vs -10.3−16.2 vs placeboNCT0079019224 other results
| -13.2 vs -2.9−10.3 vs placeboNCT0059057716 other results
|
| CGI-S, change | -1.1 vs -1−0.1 vs placeboNCT0054971820 other results
| -1 vs 0−1 vs placeboNCT0059057719 other results
|
| PANSS response | —Not posted · NCT01143090 | —Not posted · NCT00101634 |
| PSP, change | —Not posted · NCT01143090 | 8.3 vs 1.7+6.6 vs placeboNCT0059057716 other results
|
| Relapse (% of patients) | 20.9% vs 26.6%vs QuetiapineNCT00789698 | —Not posted · NCT00101634 |
PANSS total, change
- Lurasidone
- -26.5 vs -10.3−16.2 vs placeboNCT00790192
24 other results
- -19.2 vs -17 NCT00549718
- -25.7 vs -16 NCT00615433
- -18.6 vs -10.5 NCT01911429
- -17.9 vs -13.1 NCT01614899
- -6.1 vs -2.5 NCT00711269
- -20.5 vs -17 NCT00549718
- -23.6 vs -16 NCT00615433
- -23.4 vs -17 NCT00549718
- -18.3 vs -10.5 NCT01911429
- -17.3 vs -13.1 NCT01614899
- -22.2 vs -10.3 NCT00790192
- -4.3 vs -2.5 NCT00711269
- -17.6 vs -14.5 NCT01821378
- -24.9 vs -14.5 NCT01821378
- -31.2 vs -34.9 NCT02002832
- -21.7 vs -14.4 NCT01821378
- -14.4 vs -14.4 NCT01821378
- 8.3 vs 12.4 NCT01435928
- -34.6 vs -25.7 NCT00789698
- -14.1 vs -5.5 NCT00088634
- -7.1 vs -12.3 NCT00044044
- -7.2 vs -12.3 NCT00044044
- -13.6 vs -12.3 NCT00044044
- -26.4 vs -27.3 NCT03465787
- Paliperidone palmitate (Invega Sustenna)
- -13.2 vs -2.9−10.3 vs placeboNCT00590577
16 other results
- -11.6 vs -2.9 NCT00590577
- -8 vs -2.9 NCT00590577
- -18.6 vs -17.9 NCT00589914
- -1.8 vs -1.6 NCT03345342
- -21.8 vs -21.2 NCT01081769
- -19.5 vs -20.1 NCT01081769
- -21.7 vs -21.9 NCT01081769
- -18.5 vs -18.6 NCT01081769
- -23.5 vs -22.8 NCT01081769
- -16.2 vs -16.8 NCT01081769
- -14.5 vs -15 NCT01081769
- -24.3 vs -23.7 NCT01081769
- -12.2 vs -12.3 NCT01081769
- -9.4 vs -8.8 NCT01081769
- -4.8 vs -3.7 NCT01081769
- -25.5 vs -24.6 NCT01081769
CGI-S, change
- Lurasidone
- -1.1 vs -1−0.1 vs placeboNCT00549718
20 other results
- -1.5 vs -1.1 NCT00615433
- -1.0 vs -0.5 NCT01911429
- -0.9 vs -0.8 NCT01614899
- -1.3 vs -0.7 NCT01821378
- -1.7 vs -0.9 NCT00790192
- -1.2 vs -1 NCT00549718
- -1.4 vs -1.1 NCT00615433
- -1.4 vs -1 NCT00549718
- -0.9 vs -0.5 NCT01911429
- -1.0 vs -0.8 NCT01614899
- -1.5 vs -0.9 NCT00790192
- -0.9 vs -0.7 NCT01821378
- -1.3 vs -0.7 NCT01821378
- -0.8 vs -0.7 NCT01821378
- 0.4 vs 0.7 NCT01435928
- -1.9 vs -1.6 NCT00789698
- -0.6 vs -0.2 NCT00088634
- -0.5 vs -0.7 NCT00044044
- -0.4 vs -0.7 NCT00044044
- -0.8 vs -0.7 NCT00044044
- Paliperidone palmitate (Invega Sustenna)
- -1 vs 0−1 vs placeboNCT00590577
19 other results
- -1 vs 0 NCT00590577
- -1 vs 0 NCT00590577
- 0 vs 0 NCT03345342
- -1 vs -1 NCT01081769
- -0.9 vs -0.9 NCT01081769
- -0.9 vs -1 NCT01081769
- -0.8 vs -0.8 NCT01081769
- -1 vs -1 NCT01081769
- -0.7 vs -0.8 NCT01081769
- -0.6 vs -0.6 NCT01081769
- -1 vs -1.1 NCT01081769
- -0.9 vs -0.9 NCT00589914
- -0.4 vs -0.5 NCT01081769
- -0.3 vs -0.3 NCT01081769
- -0.1 vs -0.1 NCT01081769
- -1.1 vs -1.1 NCT01081769
- -0.2 vs -0.3 NCT02431702
- -0.7 vs -0.7 NCT02431702
- -0.5 vs -0.4 NCT01157351
PANSS response
- Lurasidone
- —Not posted · NCT01143090
- Paliperidone palmitate (Invega Sustenna)
- —Not posted · NCT00101634
PSP, change
- Lurasidone
- —Not posted · NCT01143090
- Paliperidone palmitate (Invega Sustenna)
- 8.3 vs 1.7+6.6 vs placeboNCT00590577
16 other results
- 6.1 vs 1.7 NCT00590577
- 2.9 vs 1.7 NCT00590577
- 15.2 vs 14.6 NCT01081769
- 14.7 vs 14 NCT01081769
- 14 vs 13.3 NCT01081769
- 12.9 vs 12.9 NCT01081769
- 1 vs 1.1 NCT03345342
- 12.7 vs 12.3 NCT01081769
- 11.4 vs 11.9 NCT01081769
- 9.9 vs 10.8 NCT01081769
- 7.6 vs 7.7 NCT01081769
- 8.5 vs 8.8 NCT00589914
- 4.9 vs 4.3 NCT01081769
- 7.5 vs 7 NCT02431702
- 2.5 vs 2.9 NCT02431702
- 5.8 vs 5.4 NCT01157351
Relapse (% of patients)
- Lurasidone
- 20.9% vs 26.6%vs QuetiapineNCT00789698
- Paliperidone palmitate (Invega Sustenna)
- —Not posted · NCT00101634
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Lurasidone: 7 of 7 rows · Paliperidone palmitate (Invega Sustenna): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lurasidone Rows use multiple source trials | Paliperidone palmitate (Invega Sustenna) Rows use multiple source trials |
|---|---|---|
| EQ-5D Index absolute change · score | 0.041 vs -0.042 placebo score @ 6wk20 mga,b,c,d NCT01821378 · Phase 3 · registry result, not featured evidence show 1 more dose0.095 vs -0.042 placebo score @ 6wk80-160 mg NCT01821378 · Phase 3 · registry result, not featured evidence | 0.1 vs 0.12 Oral Antipsychotics score @ 104wkb,c,d NCT01081769 · Phase 3 · registry result, not featured evidence |
| PANSS Total absolute change · score No placebo or comparator arm | -16.6 score @ 6wk160 mga,e,b,c,f NCT01821378 · Phase 3 · registry result, not featured evidence show 1 more dose-8.9 score @ 6wk80 mg NCT01821378 · Phase 3 · registry result, not featured evidence | 57.4 score @ 13.14wk150 mga,e,b,c,f NCT01606254 · Phase 2 · registry result, not featured evidence show 3 more doses60.2 score @ 13.14wk100 mg NCT01606254 · Phase 2 · registry result, not featured evidence 60.6 score @ 13.14wk150/ 50 mg NCT01606254 · Phase 2 · registry result, not featured evidence 56.4 score @ 13.14wk50 mg NCT01606254 · Phase 2 · registry result, not featured evidence |
| Time to First Relapse time to event · months | NA vs 6.31 placebo monthsb,c,g NCT01435928 · Phase 3 · registry result, not featured evidence | 20.24 vs 19.81 Oral Antipsychotics months*b,c,g NCT01081769 · Phase 3 · registry result, not featured evidence · converted to months from 616 days as posted |
| Dropout rate | 32.8%40mgh NCT00549718 · Phase 3 · monotherapy show 42 more results31.5%120mg NCT00549718 · Phase 3 · monotherapy 30.1%80mg NCT00549718 · Phase 3 · monotherapy 35.8%40 mg NCT00615433 · Phase 3 · monotherapy 44.5%120 mg NCT00615433 · Phase 3 · monotherapy 0%Lurasidone NCT02199743 · Phase 4 · registry result, not featured evidence —Lurasidone (LUR) NCT02199743 · Phase 4 · registry result, not featured evidence 33.3% NCT01569659 · Phase 4 · registry result, not featured evidence 11.1%40 mg NCT01911429 · Phase 3 · registry result, not featured evidence 9.4%80 mg NCT01911429 · Phase 3 · registry result, not featured evidence 14.4% NCT02002832 · Phase 3 · registry result, not featured evidence 44%40-mg or 80-mg NCT01614912 · Phase 3 · registry result, not featured evidence 29.3%40 mg NCT01614899 · Phase 3 · registry result, not featured evidence 25.2%80 mg NCT01614899 · Phase 3 · registry result, not featured evidence 26.7%20 mg NCT01821378 · Phase 3 · registry result, not featured evidence —80-160 mg NCT01821378 · Phase 3 · registry result, not featured evidence 75.3% NCT01485640 · Phase 3 · registry result, not featured evidence 18.8% NCT01566162 · Phase 3 · registry result, not featured evidence — NCT01435928 · Phase 3 · registry result, not featured evidence 41.8%160 mg NCT00789698 · Phase 3 · registry result, not featured evidence 55.6%80 mg NCT00789698 · Phase 3 · registry result, not featured evidence 21.6%40/40 NCT01143077 · Phase 3 · registry result, not featured evidence 17%40/80 NCT01143077 · Phase 3 · registry result, not featured evidence 18.3%80/80 NCT01143077 · Phase 3 · registry result, not featured evidence 65.6% NCT00641745 · Phase 3 · registry result, not featured evidence 23.1%160 mg NCT00790192 · Phase 3 · registry result, not featured evidence 28.8%80 mg NCT00790192 · Phase 3 · registry result, not featured evidence 33.6%40 mg NCT00711269 · Phase 3 · registry result, not featured evidence 36.6%80 mg NCT00711269 · Phase 3 · registry result, not featured evidence 22.2%flexible dose NCT01731119 · Phase 2 · registry result, not featured evidence 88.5%80 mg NCT00088621 · Phase 2 · registry result, not featured evidence 42.2%80 mg NCT00088634 · Phase 2 · registry result, not featured evidence 42.4%40 mg NCT00044005 · Phase 2 · registry result, not featured evidence 66.7%80 mg NCT00044005 · Phase 2 · registry result, not featured evidence 59.4%20 mg NCT00044005 · Phase 2 · registry result, not featured evidence 62%20 mg NCT00044044 · Phase 2 · registry result, not featured evidence 59.4%40 mg NCT00044044 · Phase 2 · registry result, not featured evidence 56.3%80 mg NCT00044044 · Phase 2 · registry result, not featured evidence 0%40 mg NCT02174510 · Phase 1 · registry result, not featured evidence 0%80 mg NCT02174510 · Phase 1 · registry result, not featured evidence 0%20 mg NCT02174510 · Phase 1 · registry result, not featured evidence 10%40mg NCT02174523 · Phase 1 · registry result, not featured evidence 14.3% NCT01620060 · Phase 1 · registry result, not featured evidence | —Part 2-Paliperidone Palmitate (PP)i NCT02431702 · Phase 3 show 16 more results—Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 —Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 59.6% NCT01157351 · Phase 4 · registry result, not featured evidence —Double-blind PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 —Follow-up Phase PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 6.4% NCT01081769 · Phase 3 · registry result, not featured evidence 40.3%Paliperidone Palmitate (Double-bli NCT01299389 · Phase 3 · registry result, not featured evidence —Paliperidone Palmitate (Post-0bser NCT01299389 · Phase 3 · registry result, not featured evidence 24.8% NCT00589914 · Phase 3 · registry result, not featured evidence 44.8%150 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 46.1%100 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 48.1%25 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 0%150 mg NCT01606254 · Phase 2 · registry result, not featured evidence 28.6%100 mg NCT01606254 · Phase 2 · registry result, not featured evidence 21.4%150/ 50 mg NCT01606254 · Phase 2 · registry result, not featured evidence 14.3%50 mg NCT01606254 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 4.8%40mgh NCT00549718 · Phase 3 · monotherapy show 42 more results5.6%120mg NCT00549718 · Phase 3 · monotherapy 6.5%80mg NCT00549718 · Phase 3 · monotherapy —40 mg NCT00615433 · Phase 3 · monotherapy —120 mg NCT00615433 · Phase 3 · monotherapy —Lurasidone NCT02199743 · Phase 4 · registry result, not featured evidence —Lurasidone (LUR) NCT02199743 · Phase 4 · registry result, not featured evidence — NCT01569659 · Phase 4 · registry result, not featured evidence 4.6%40 mg NCT01911429 · Phase 3 · registry result, not featured evidence 2.8%80 mg NCT01911429 · Phase 3 · registry result, not featured evidence — NCT02002832 · Phase 3 · registry result, not featured evidence —40-mg or 80-mg NCT01614912 · Phase 3 · registry result, not featured evidence —40 mg NCT01614899 · Phase 3 · registry result, not featured evidence —80 mg NCT01614899 · Phase 3 · registry result, not featured evidence —20 mg NCT01821378 · Phase 3 · registry result, not featured evidence —80-160 mg NCT01821378 · Phase 3 · registry result, not featured evidence 6.2% NCT01485640 · Phase 3 · registry result, not featured evidence — NCT01566162 · Phase 3 · registry result, not featured evidence — NCT01435928 · Phase 3 · registry result, not featured evidence 6.3%160 mg NCT00789698 · Phase 3 · registry result, not featured evidence 6.9%80 mg NCT00789698 · Phase 3 · registry result, not featured evidence 6.8%40/40 NCT01143077 · Phase 3 · registry result, not featured evidence 6.8%40/80 NCT01143077 · Phase 3 · registry result, not featured evidence 6.1%80/80 NCT01143077 · Phase 3 · registry result, not featured evidence — NCT00641745 · Phase 3 · registry result, not featured evidence —160 mg NCT00790192 · Phase 3 · registry result, not featured evidence —80 mg NCT00790192 · Phase 3 · registry result, not featured evidence —40 mg NCT00711269 · Phase 3 · registry result, not featured evidence —80 mg NCT00711269 · Phase 3 · registry result, not featured evidence —flexible dose NCT01731119 · Phase 2 · registry result, not featured evidence —80 mg NCT00088621 · Phase 2 · registry result, not featured evidence —80 mg NCT00088634 · Phase 2 · registry result, not featured evidence —40 mg NCT00044005 · Phase 2 · registry result, not featured evidence —80 mg NCT00044005 · Phase 2 · registry result, not featured evidence —20 mg NCT00044005 · Phase 2 · registry result, not featured evidence —20 mg NCT00044044 · Phase 2 · registry result, not featured evidence —40 mg NCT00044044 · Phase 2 · registry result, not featured evidence —80 mg NCT00044044 · Phase 2 · registry result, not featured evidence —40 mg NCT02174510 · Phase 1 · registry result, not featured evidence —80 mg NCT02174510 · Phase 1 · registry result, not featured evidence —20 mg NCT02174510 · Phase 1 · registry result, not featured evidence —40mg NCT02174523 · Phase 1 · registry result, not featured evidence 8.6% NCT01620060 · Phase 1 · registry result, not featured evidence | —Part 2-Paliperidone Palmitate (PP)i NCT02431702 · Phase 3 show 16 more results—Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 —Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 2.2% NCT01157351 · Phase 4 · registry result, not featured evidence —Double-blind PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 —Follow-up Phase PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 — NCT01081769 · Phase 3 · registry result, not featured evidence 17%Paliperidone Palmitate (Double-bli NCT01299389 · Phase 3 · registry result, not featured evidence —Paliperidone Palmitate (Post-0bser NCT01299389 · Phase 3 · registry result, not featured evidence 3.1% NCT00589914 · Phase 3 · registry result, not featured evidence 8%150 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 6.1%100 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 6.3%25 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 0%150 mg NCT01606254 · Phase 2 · registry result, not featured evidence 7.1%100 mg NCT01606254 · Phase 2 · registry result, not featured evidence 7.1%150/ 50 mg NCT01606254 · Phase 2 · registry result, not featured evidence 7.1%50 mg NCT01606254 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 1.6%40mgh NCT00549718 · Phase 3 · monotherapy show 42 more results4.8%120mg NCT00549718 · Phase 3 · monotherapy 2.5%80mg NCT00549718 · Phase 3 · monotherapy 1.7%40 mg NCT00615433 · Phase 3 · monotherapy 5.1%120 mg NCT00615433 · Phase 3 · monotherapy —Lurasidone NCT02199743 · Phase 4 · registry result, not featured evidence 7.1%Lurasidone (LUR) NCT02199743 · Phase 4 · registry result, not featured evidence 3% NCT01569659 · Phase 4 · registry result, not featured evidence 3.6%40 mg NCT01911429 · Phase 3 · registry result, not featured evidence 1.9%80 mg NCT01911429 · Phase 3 · registry result, not featured evidence 0.5% NCT02002832 · Phase 3 · registry result, not featured evidence 11%40-mg or 80-mg NCT01614912 · Phase 3 · registry result, not featured evidence 2.7%40 mg NCT01614899 · Phase 3 · registry result, not featured evidence 1.9%80 mg NCT01614899 · Phase 3 · registry result, not featured evidence 3%20 mg NCT01821378 · Phase 3 · registry result, not featured evidence 3%80-160 mg NCT01821378 · Phase 3 · registry result, not featured evidence 4.3% NCT01485640 · Phase 3 · registry result, not featured evidence 6.8% NCT01566162 · Phase 3 · registry result, not featured evidence 4.2% NCT01435928 · Phase 3 · registry result, not featured evidence 7.6%160 mg NCT00789698 · Phase 3 · registry result, not featured evidence 12.5%80 mg NCT00789698 · Phase 3 · registry result, not featured evidence 4.2%40/40 NCT01143077 · Phase 3 · registry result, not featured evidence 2.3%40/80 NCT01143077 · Phase 3 · registry result, not featured evidence 0%80/80 NCT01143077 · Phase 3 · registry result, not featured evidence 11% NCT00641745 · Phase 3 · registry result, not featured evidence 3.3%160 mg NCT00790192 · Phase 3 · registry result, not featured evidence 0.8%80 mg NCT00790192 · Phase 3 · registry result, not featured evidence 6.3%40 mg NCT00711269 · Phase 3 · registry result, not featured evidence 5.3%80 mg NCT00711269 · Phase 3 · registry result, not featured evidence 0%flexible dose NCT01731119 · Phase 2 · registry result, not featured evidence 20.3%80 mg NCT00088621 · Phase 2 · registry result, not featured evidence 2.2%80 mg NCT00088634 · Phase 2 · registry result, not featured evidence 18.2%40 mg NCT00044005 · Phase 2 · registry result, not featured evidence 9.1%80 mg NCT00044005 · Phase 2 · registry result, not featured evidence 9.4%20 mg NCT00044005 · Phase 2 · registry result, not featured evidence 5.6%20 mg NCT00044044 · Phase 2 · registry result, not featured evidence 13.4%40 mg NCT00044044 · Phase 2 · registry result, not featured evidence 4.2%80 mg NCT00044044 · Phase 2 · registry result, not featured evidence 0%40 mg NCT02174510 · Phase 1 · registry result, not featured evidence 0%80 mg NCT02174510 · Phase 1 · registry result, not featured evidence 0%20 mg NCT02174510 · Phase 1 · registry result, not featured evidence 0%40mg NCT02174523 · Phase 1 · registry result, not featured evidence 1.9% NCT01620060 · Phase 1 · registry result, not featured evidence | 12.8%Part 2-Paliperidone Palmitate (PP)i NCT02431702 · Phase 3 show 16 more results5.3%Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 2%Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 18.6% NCT01157351 · Phase 4 · registry result, not featured evidence 5%Double-blind PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 5.5%Follow-up Phase PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 11.2% NCT01081769 · Phase 3 · registry result, not featured evidence 6.3%Paliperidone Palmitate (Double-bli NCT01299389 · Phase 3 · registry result, not featured evidence 3.9%Paliperidone Palmitate (Post-0bser NCT01299389 · Phase 3 · registry result, not featured evidence 6.8% NCT00589914 · Phase 3 · registry result, not featured evidence —150 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence —100 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence —25 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 14.3%150 mg NCT01606254 · Phase 2 · registry result, not featured evidence 0%100 mg NCT01606254 · Phase 2 · registry result, not featured evidence 21.4%150/ 50 mg NCT01606254 · Phase 2 · registry result, not featured evidence 7.1%50 mg NCT01606254 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 40mgh headache 18.5% (placebo 15.7%) akathisia 11.3% (placebo 51.2%) nausea 11.3% (placebo 7.1%) NCT00549718 · Phase 3 · monotherapy show 41 more results120mg akathisia 24.2% (placebo 51.2%) headache 16.9% (placebo 15.7%) somnolence 14.5% (placebo 5.5%) NCT00549718 · Phase 3 · monotherapy 80mg akathisia 17.4% (placebo 51.2%) headache 13.2% (placebo 15.7%) sedation 10.7% (placebo 4.7%) NCT00549718 · Phase 3 · monotherapy 40 mg headache 21.8% (placebo 21.6%) insomnia 12.6% (placebo 11.2%) akathisia 11.8% (placebo 0.9%) NCT00615433 · Phase 3 · monotherapy 120 mg akathisia 22.9% (placebo 0.9%) headache 17.8% (placebo 21.6%) somnolence 15.3% (placebo 4.3%) NCT00615433 · Phase 3 · monotherapy insomnia 21.4% sedation 21.4% stiffness in jaw 14.3% NCT02199743 · Phase 4 · registry result, not featured evidence nausea 27.3% headache 15.2% insomnia 12.1% NCT01569659 · Phase 4 · registry result, not featured evidence 40 mg nausea 12.7% (placebo 2.7%) anxiety 10% (placebo 8%) akathisia 9.1% (placebo 1.8%) NCT01911429 · Phase 3 · registry result, not featured evidence 80 mg nausea 14.4% (placebo 2.7%) somnolence 11.5% (placebo 5.4%) headache 10.6% (placebo 12.5%) NCT01911429 · Phase 3 · registry result, not featured evidence extrapyramidal disorder 17% consitpation 12.9% insomnia 9.8% NCT02002832 · Phase 3 · registry result, not featured evidence 40-mg or 80-mg insomnia 11.3% akathisia 11% nasopharyngitis 10.6% NCT01614912 · Phase 3 · registry result, not featured evidence 40 mg headache 9.3% (placebo 7.9%) constipation 8.7% (placebo 7.9%) akathisia 7.3% (placebo 3.3%) NCT01614899 · Phase 3 · registry result, not featured evidence 80 mg akathisia 10.4% (placebo 3.3%) nausea 7.8% (placebo 4.6%) anxiety 7.1% (placebo 5.3%) NCT01614899 · Phase 3 · registry result, not featured evidence 20 mg insomnia 15.8% (placebo 21.4%) headache 9.9% (placebo 7.1%) anxiety 7.9% (placebo 6.3%) NCT01821378 · Phase 3 · registry result, not featured evidence 80-160 mg akathisia 10.6% (placebo 1.8%) insomnia 10.6% (placebo 21.4%) nausea 8.6% (placebo 3.6%) NCT01821378 · Phase 3 · registry result, not featured evidence headache 5.6% diarrhoea 3.7% influenza 3.7% NCT01485640 · Phase 3 · registry result, not featured evidence akathisia 5.2% schizophrenia 4.2% nasopharyngitis 2.6% NCT01566162 · Phase 3 · registry result, not featured evidence schizophrenia 6.9% (placebo 7.8%) insomnia 6.3% (placebo 7.1%) anxiety 4.2% (placebo 2.8%) NCT01435928 · Phase 3 · registry result, not featured evidence 160 mg headache 13.9% akathisia 10.1% insomnia 8.9% NCT00789698 · Phase 3 · registry result, not featured evidence 80 mg akathisia 15.3% headache 6.9% insomnia 6.9% NCT00789698 · Phase 3 · registry result, not featured evidence 40/40 nausea 13.9% headache 9.7% somnolence 9.7% NCT01143077 · Phase 3 · registry result, not featured evidence 40/80 insomnia 18.4% akathisia 14.9% headache 11.5% NCT01143077 · Phase 3 · registry result, not featured evidence 80/80 nausea 18.5% insomnia 14.8% akathisia 13.6% NCT01143077 · Phase 3 · registry result, not featured evidence nausea 16.7% insomnia 15.8% sedation 14.6% NCT00641745 · Phase 3 · registry result, not featured evidence 160 mg headache 9.9% (placebo 10.7%) akathisia 7.4% (placebo 0.8%) vomiting 7.4% (placebo 5%) NCT00790192 · Phase 3 · registry result, not featured evidence 80 mg insomnia 11.2% (placebo 9.1%) headache 9.6% (placebo 10.7%) akathisia 8% (placebo 0.8%) NCT00790192 · Phase 3 · registry result, not featured evidence 40 mg insomnia 14.2% (placebo 14.4%) schizophrenia 11.8% (placebo 18.9%) nasopharyngitis 10.2% (placebo 9.8%) NCT00711269 · Phase 3 · registry result, not featured evidence 80 mg insomnia 19.1% (placebo 14.4%) schizophrenia 19.1% (placebo 18.9%) akathisia 11.5% (placebo 4.5%) NCT00711269 · Phase 3 · registry result, not featured evidence 80 mg bronchitis 6.8% nausea 6.8% sedation 6.8% NCT00088621 · Phase 2 · registry result, not featured evidence 80 mg nausea 16.7% (placebo 3.3%) constipation 11.1% (placebo 5.6%) headache 11.1% (placebo 10%) NCT00088634 · Phase 2 · registry result, not featured evidence 40 mg dizziness 18.2% headache 15.2% nasopharyngitis 12.1% NCT00044005 · Phase 2 · registry result, not featured evidence 80 mg headache 15.2% depression 12.1% oropharyngeal pain 9.1% NCT00044005 · Phase 2 · registry result, not featured evidence 20 mg headache 15.6% insomnia 9.4% nasopharyngitis 9.4% NCT00044005 · Phase 2 · registry result, not featured evidence headache 21.1% (placebo 33.3%) dyspepsia 11.3% (placebo 9.7%) nausea 11.3% (placebo 11.1%) NCT00044044 · Phase 2 · registry result, not featured evidence headache 23.9% (placebo 33.3%) sedation 16.4% (placebo 8.3%) agitation 13.4% (placebo 4.2%) NCT00044044 · Phase 2 · registry result, not featured evidence headache 23.9% (placebo 33.3%) sedation 21.1% (placebo 8.3%) akathisia 18.3% (placebo 9.7%) NCT00044044 · Phase 2 · registry result, not featured evidence 40 mg somnolence 75% (placebo 33.3%) blood prolactin increased 12.5% (placebo 22.2%) irritability 12.5% (placebo 0%) NCT02174510 · Phase 1 · registry result, not featured evidence 80 mg somnolence 100% (placebo 33.3%) blood prolactin increased 83.3% (placebo 22.2%) dizziness 25% (placebo 0%) NCT02174510 · Phase 1 · registry result, not featured evidence 20 mg somnolence 62.5% (placebo 33.3%) blood prolactin increased 12.5% (placebo 22.2%) feeling hot 12.5% (placebo 0%) NCT02174510 · Phase 1 · registry result, not featured evidence 40mg somnolence 100% (placebo 0%) blood prolactin increased 60% (placebo 25%) restlessness 60% (placebo 0%) NCT02174523 · Phase 1 · registry result, not featured evidence somnelence 41.9% sedation 18.1% nausea 17.1% NCT01620060 · Phase 1 · registry result, not featured evidence | show 16 more resultsinjection site pain 18.6% insomnia 18.6% weight increased 13.3% NCT01157351 · Phase 4 · registry result, not featured evidence weight increased 8.4% injection site pain 7.7% headache 6.7% NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 nasopharyngitis 3.7% upper respiratory tract infection 0.9% headache 0% NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 weight increased 15.4% insomnia 11.2% headache 10.6% NCT01081769 · Phase 3 · registry result, not featured evidence insomnia 17% (placebo 15.2%) injection site pain 13.2% (placebo 6.7%) nasopharyngitis 12.6% (placebo 6.1%) NCT01299389 · Phase 3 · registry result, not featured evidence nasopharyngitis 8.4% (placebo 6.1%) constipation 5.2% (placebo 5.5%) insomnia 3.9% (placebo 15.2%) NCT01299389 · Phase 3 · registry result, not featured evidence insomnia 9.4% headache 7.1% somnolence 5.6% NCT00589914 · Phase 3 · registry result, not featured evidence 150 mg eq. injection site pain 8% (placebo 3.7%) headache 6.1% (placebo 7.3%) akathisia 5.5% (placebo 4.9%) NCT00590577 · Phase 3 · registry result, not featured evidence 100 mg eq. headache 6.7% (placebo 7.3%) injection site pain 6.1% (placebo 3.7%) akathisia 4.8% (placebo 4.9%) NCT00590577 · Phase 3 · registry result, not featured evidence 25 mg eq. headache 10.6% (placebo 7.3%) injection site pain 8.8% (placebo 3.7%) akathisia 1.3% (placebo 4.9%) NCT00590577 · Phase 3 · registry result, not featured evidence 150 mg blood prolactin increased 92.9% insomnia 28.6% nasopharyngitis 28.6% NCT01606254 · Phase 2 · registry result, not featured evidence 100 mg blood prolactin increased 64.3% psychiatric symptom 42.9% nasopharyngitis 28.6% NCT01606254 · Phase 2 · registry result, not featured evidence 150/ 50 mg blood prolactin increased 71.4% nasopharyngitis 28.6% alanine aminotransferase increased 21.4% NCT01606254 · Phase 2 · registry result, not featured evidence 50 mg blood prolactin increased 78.6% nasopharyngitis 35.7% psychiatric symptom 35.7% NCT01606254 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 104 weeks versus 6 weeks.
- eTrial phases differ: Phase 2 versus Phase 3.
- fAssessment timepoints differ: 13.14 weeks versus 6 weeks.
- gThe assessment timepoint is not available for both results.
- hPopulation comparability has not been reviewed for these studies.
- iPopulation comparability has not been reviewed for 15 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lurasidone
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 5 more results
show 1 more result
show 1 more result
show 1 more result
+ 15 further endpoints in the CSV export.
Paliperidone palmitate (Invega Sustenna)
show 2 more results
show 3 more results
show 16 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 14 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lurasidone's landscape · Paliperidone palmitate (Invega Sustenna)'s landscape